Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Equity Income (2016 - 2020)

Ligand Pharmaceuticals (LGNDZ) has disclosed Equity Income for 6 consecutive years, with -$25.5 million as the latest value for Q1 2020.

  • Quarterly Equity Income fell 247.2% to -$25.5 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was -$39.9 million through Mar 2020, down 192.66% year-over-year, with the annual reading at $2.9 million for FY2019, 93.94% down from the prior year.
  • Equity Income hit -$25.5 million in Q1 2020 for Ligand Pharmaceuticals, down from $8.5 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $59.9 million in Q3 2018 to a low of -$74.0 million in Q4 2018.
  • Historically, Equity Income has averaged $180705.9 across 5 years, with a median of -$1.2 million in 2017.
  • Biggest YoY gain for Equity Income was 5975.47% in 2018; the steepest drop was 1758.18% in 2018.
  • Year by year, Equity Income stood at -$9.0 million in 2016, then skyrocketed by 149.64% to $4.5 million in 2017, then crashed by 1758.18% to -$74.0 million in 2018, then surged by 111.46% to $8.5 million in 2019, then crashed by 400.19% to -$25.5 million in 2020.
  • Business Quant data shows Equity Income for LGNDZ at -$25.5 million in Q1 2020, $8.5 million in Q4 2019, and -$10.5 million in Q3 2019.